Entera Bio Ltd

ENTX

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    20

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,365.7024.700.30%
CAC 407,593.8738.000.50%
DAX 4022,496.9871.150.32%
Dow JONES (US)40,669.36141.740.35%
FTSE 1008,496.581.730.02%
HKSE22,119.41111.300.51%
NASDAQ17,446.3414.98-0.09%
Nikkei 22536,452.30406.921.13%
NZX 50 Index12,148.60245.292.06%
S&P 5005,569.068.230.15%
S&P/ASX 2008,145.6019.400.24%
SSE Composite Index3,279.037.62-0.23%

Market Movers